K
Kanyos Bio
Founded with the goal of developing antigen-specific immune tolerance technology for two specific autoimmune indications, type-1 diabetes and celiac disease
About Kanyos Bio
Kanyos.com is the online platform for Anokion, a pioneering biotech startup that operates in the healthcare sector, specifically focusing on autoimmune diseases. The company's primary objective is to develop a more effective approach to treat autoimmune diseases, which are conditions where the body's immune system mistakenly attacks its own cells.
Anokion's unique selling proposition lies in its proprietary immune tolerance platform. This platform utilizes specially engineered proteins, known as antigens, to deliver targeted disease therapy. Unlike traditional treatments, Anokion's approach aims to avoid the side effects of broad immunosuppression, which is a general reduction of the body's immune response.
The company's antigen-specific platform is highly versatile and can be adapted to virtually any antigen-mediated disease. This means it has the potential to be used across a wide range of clinical applications, making it a game-changer in the healthcare industry.
Anokion's business model is based on the research, development, and commercialization of its immune tolerance platform. The company generates revenue by developing and selling its innovative treatments to healthcare providers who serve patients suffering from autoimmune diseases.
In summary, Anokion is a biotech startup that is revolutionizing the treatment of autoimmune diseases by harnessing the body's natural tolerance pathways and targeting disease-causing antigens.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2015
- Headquarters
- Cambridge, United States
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 58.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Personal Health, Diabetes, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Sep 2019 | $0 | — | Anokion | — |
| EARLY VC✓Equity / VC | Jun 2015 | $16M | $66M | Novartis Venture Fund · Novo Ventures | — |
Growth signals
Latest recorded traffic for Kanyos Bio is 0 monthly website visits. Kanyos Bio's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Novartis Venture Fund
Novo Ventures
Other known investors2 additional known investors
Anokion
EPFL Swiss Federal Polytechnic School of Lausanne
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kanyos Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kanyos Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.